Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Low protein diet · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Low protein diet |
| Name | Type | Description |
|---|---|---|
| Low protein diet | OTHER | Low protein diet for 6.5 weeks |
Inclusion Criteria: * Healthy Asian or Caucasian women between the ages of 20-40 years. Exclusion Criteria: * Diseases or medical conditions: gastrointestinal diseases, osteoporosis, diabetes, hypertension, liver disease, thyroid disorders, kidney disease, kidney stones, cancer, heart disease, ea...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Precision BioSciences, Inc. | DTIL | 1 | N/A | Undisclosed |
| SI-BONE, Inc. | SIBN | 1 | - | Undisclosed |
Low protein diet is an investigational nutritional intervention being studied for its effects on calcium metabolism in osteoporosis. It is a dietary approach, not a conventional drug, and is currently in Phase 1 clinical development. The therapy is being evaluated in a completed trial involving 11 female participants in the United States.
Low protein diet is being developed by United Therapeutics Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker UTHR. The company is conducting clinical research to evaluate the effects of this nutritional intervention on calcium metabolism in the context of osteoporosis.
Low protein diet is in Phase 1 clinical development. It is an investigational nutritional intervention, not yet approved by regulatory authorities. The Phase 1 trial has been completed, and the product remains in early-stage clinical research for its potential use in osteoporosis.
Low protein diet has one completed clinical trial, NCT00671944, titled 'Long-term Nutritional Intervention Study to Determine How Protein Affects Calcium Metabolism.' This Phase 1 study enrolled 11 female participants in the United States and focused on osteoporosis. The trial was uncontrolled and not randomized or double-blinded.
Low protein diet is not FDA approved. It is an investigational nutritional intervention currently in Phase 1 clinical development. The completed trial, NCT00671944, was an early-stage study, and the product has not yet received regulatory approval for any indication, including osteoporosis.